Company Profiles

driven by the PitchBook Platform

Axikin Pharmaceuticals

Description

Operator of a bio-pharmaceutical platform designed to offer novel therapeutics for respiratory disorders. The company's bio-pharmaceutical platform develops and commercializes small molecule therapeutics for respiratory, inflammatory, and autoimmune diseases as well as develops novel GPCR, the antagonism of which is predicted to ameliorate allergic respiratory disorders, enabling healthcare professionals treat diseases like rhinitis and asthma, in addition to significantly intimating the inflammation observed in COPD.

2008

Founded

PRIVATE

Status

11-50

Employees

Later Stage VC

Latest Deal Type

$6.5M

Latest Deal Amount

$11.6M

Total Amount Raised

Description

Operator of a bio-pharmaceutical platform designed to offer novel therapeutics for respiratory disorders. The company's bio-pharmaceutical platform develops and commercializes small molecule therapeutics for respiratory, inflammatory, and autoimmune diseases as well as develops novel GPCR, the antagonism of which is predicted to ameliorate allergic respiratory disorders, enabling healthcare professionals treat diseases like rhinitis and asthma, in addition to significantly intimating the inflammation observed in COPD.

Website:

www.axikin.com

Ownership Status

Privately Held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Drug Discovery

Other Industries

Other Pharmaceuticals and Biotechnology

Primary Office

6185 Cornerstone Court Suite 106 San Diego, CA 92121United States +1 (858) 458-1890
    Request a free trial to the PitchBook Platform
    You're viewing a free company profile from the PitchBook Platform. To explore Axikin Pharmaceuticals's full profile, request a free trial.

    Axikin Pharmaceuticals Valuation and Funding

    Request access
    Deal TypeDateAmountRaised to DatePost-ValStatusStage

    Axikin Pharmaceuticals Cap Table

    Stock# of Shares
    Authorized
    Par ValueDividend Rate (%)Original
    Issue Price
    LiquidationLiquidation
    Pref. Multiple
    Conversion
    Price
    % Owned

    Axikin Pharmaceuticals Investors (2)

    Request access
    Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
    Seat
    Contact
    Info
    Mitsui Global InvestmentCorporate Venture CapitalMinority000 0000000 0000
    Sanderling VenturesVenture CapitalMinority000 0000000 0000
    Mitsui Global Investment Corporate Venture Capital
    Sanderling Ventures Venture Capital

    Axikin Pharmaceuticals Executive Team (4)

    NameTitleBoard
    Seat
    Contact
    Info
    Kevin Bacon Ph.DPresident, Founder, Chief Scientific Officer & Board Member
    Stefen Boehme Ph.DDirector, Immunology
    Tai Ly Ph.DSenior Director, Drug Development Technologies
    Peter McWilliams Ph.DActing Chief Executive Officer & Chairman
    Kevin Bacon Ph.D President, Founder, Chief Scientific Officer & Board Member
    Stefen Boehme Ph.D Director, Immunology
    Tai Ly Ph.D Senior Director, Drug Development Technologies
    Peter McWilliams Ph.D Acting Chief Executive Officer & Chairman

    Axikin Pharmaceuticals Board Members (2)

    NameRepresentingRoleSinceContact
    Info
    Fred MiddletonSanderling VenturesManaging Director000 0000
    Peter McWilliams Ph.DSelfActing Chief Executive Officer & Chairman000 0000
    Fred Middleton Managing Director Sanderling Ventures
    Peter McWilliams Ph.D Acting Chief Executive Officer & Chairman Self
    Request full access to PitchBook